Featured speaker of the week: Kim Bill, a homegrown expert in international business development and licensing in the biopharma industry

Kim Bill
Vice-President, Corporate Development, Debiopharm S.A., Switzerland
Founder, Asia Life Sciences Academy Pte Ltd, Singapore

Kim Bill is a renowned expert and trainer in biotech and pharma business development and licensing. With over 25 years of senior international experience in the industry in Scientific Affairs, Regulatory, Marketing, Business and Corporate Development, she negotiated and closed numerous in and out licensing, investment and collaboration deals.

Kim Bill graduated from the National University of Singapore with a degree in Pharmacy. Later on she earned a Masters in Business Administration at the University of Hull in the UK and General and Marketing Management with Stanford University in the US and Bocconi University in Italy.

Currently, she is Vice-President, Corporate Development at the Debiopharm Corporate Group in Switzerland, responsible for strategic deals and investment opportunities. She has worked at Debiopharm for over 13 years in Business Development, Licensing, Legal and Communications and was on the Management Board for over 8 years. Kim founded Asia Life Sciences Academy Pte Ltd in Singapore to provide bio-pharmaceutical training in partnership with universities and institutions in the Asian region. She serves on the Board of Directors of Aurigene Discovery Technologies, a fully integrated drug discovery biotech in Bangalore, India as well as on the Board of the Swiss Pharma Licensing Group. Her extensive experience comes from previous positions including Marketing Executive for Diethlem Pte Ltd, Marketing Director at Les Laboratories Servier in Paris before moving to MerckSerono as Director of Scientific Affairs in the Asia-Pacific region. In the late eighties she re-located to Switzerland to hold positions in European and International Operations in Sales and Marketing, Business Development and Management, including setting up subsidiaries in the then socialist Central and Eastern Europe and the USSR.

Click here to see her article featured in the January 2011 issue of Pharma Asia, which provides a thoughtful overview of business development in the Asian biopharma industry.

——————————————————————————-

Like what you read from Kim Bill’s article? Hear from her directly at Pharma Partnering & Investment World Asia 2011, where she will be discussing “Opportunities in investing in early stage companies”.